Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Boosted by PNC Financial Services Group Inc.

Key Points

• PNC Financial Services Group Inc. increased its stake in Genmab A/S Sponsored ADR by 34.9%, owning 100,529 shares valued at approximately $1.97 million by the end of the reporting period.
• Genmab's stock has a market capitalization of $13.75 billion, with a 52-week range between $17.24 and $27.94, as well as a P/E ratio of 10.77.
• Analysts have shown a positive outlook for Genmab, with several firms raising their price targets, and the stock currently holding an average rating of "Moderate Buy".

PNC Financial Services Group Inc. grew its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 34.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,529 shares of the company's stock after purchasing an additional 26,027 shares during the period. PNC Financial Services Group Inc.'s holdings in Genmab A/S were worth $1,968,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of GMAB. Deep Track Capital LP acquired a new stake in Genmab A/S during the 4th quarter worth approximately $41,740,000. Two Sigma Advisers LP lifted its stake in Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after purchasing an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP lifted its stake in Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Marshall Wace LLP lifted its stake in Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after purchasing an additional 694,243 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Genmab A/S during the fourth quarter worth $12,360,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Truist Financial raised their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Trading Up 3.0%

NASDAQ:GMAB traded up $0.66 during mid-day trading on Wednesday, reaching $22.53. 359,023 shares of the stock were exchanged, compared to its average volume of 1,445,724. The business has a fifty day moving average price of $21.74 and a 200 day moving average price of $20.87. The firm has a market capitalization of $14.46 billion, a PE ratio of 11.32, a PEG ratio of 6.19 and a beta of 0.95. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $27.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. On average, sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.